Cerus Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vivek K. Jayaraman
- Full Time Employees
- 275
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1220 Concord Avenue Concord CA United States 94520
- IPO Date
- Jan 31, 1997
- CIK
- 0001020214
- Website
- cerus.com
- Similar Companies
- Business
- Cerus Corporation (Nasdaq: CERS), headquartered in Concord, California and founded in 1991, develops and commercializes the INTERCEPT Blood System, a pathogen reduction technology designed to safeguard platelet, plasma and cryoprecipitate blood components against bacterial contamination, viruses and other pathogens for transfusion to patients; the system employs a photochemical treatment process using amotosalen and ultraviolet A light illumination, followed by the use of the INTERCEPT processing sets and accessories including platelet and plasma containers, illumination devices, and transfer sets. Core products include the INTERCEPT Blood System for platelets and plasma, approved by the FDA and bearing CE mark in Europe and available in the United States, Europe, the Middle East, the Commonwealth of Independent States, Latin America and other international markets through direct sales forces and distributors; the INTERCEPT Blood System for Cryoprecipitation, which produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex or IFC) approved in the US for treating bleeding associated with fibrinogen deficiency including massive hemorrhage; and the INTERCEPT Blood System for red blood cells, currently in late-stage clinical development. The company also offers implementation, training, technical support and maintenance services to facilitate adoption by blood centers and hospitals; it targets healthcare providers such as blood collection organizations, hospitals and ultimately patients reliant on safe transfusions within the biotechnology and medical devices sectors focused on transfusion medicine and blood safety. Recent developments include record third quarter 2025 results with raised full-year 2025 product revenue guidance driven by strong North American platelet growth, IFC business expansion and increased production capacity; an extended supply agreement with Porex Corporation effective January 1, 2025 through December 31, 2027 for platelet wafers and plasma disks ensuring supply chain stability with fixed pricing for the first two years; plans to launch an LED illuminator in Europe in 2025 and the US in 2026; a $248 million BARDA contract to advance the INTERCEPT red blood cell program; and a formal recommendation from the German National Blood Advisory Committee for enhancing platelet transfusion safety using pathogen reduction.
Company News
Cerus: 3 Key Takeaways for Long-Term Investors
Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript
Cerus Q3 Earnings Call Highlights
Cerus' blood-safety system meets main goal in late-stage trial
Cerus Corporation Announces Third Quarter 2026 Financial Results
Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical Analysis
Cerus: This Blood-Safety Underdog Should Be Earning More Respect
Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS
Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
Cerus Q2 Earnings Call Highlights
Cerus Corporation Announces Second Quarter 2026 Financial Results
Amova Asset Management Americas Inc. Sells 193,353 Shares of Cerus Corporation $CERS
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis